Uniqure (QURE) Stock Price Down 6.9% After Insider Selling
Uniqure NV (NASDAQ:QURE) dropped 6.9% during mid-day trading on Monday following insider selling activity. The company traded as low as $17.08 and last traded at $18.13. Approximately 761,901 shares changed hands during trading, an increase of 56% from the average daily volume of 487,460 shares. The stock had previously closed at $19.48.
Specifically, CEO Matthew C. Kapusta sold 21,690 shares of Uniqure stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $19.87, for a total transaction of $430,980.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christian Klemt sold 5,093 shares of Uniqure stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total value of $102,522.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,647 shares of company stock worth $651,545. Company insiders own 0.73% of the company’s stock.
QURE has been the topic of several research reports. HC Wainwright set a $28.00 target price on Uniqure and gave the company a “buy” rating in a research note on Thursday, December 7th. Janney Montgomery Scott initiated coverage on Uniqure in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 target price on the stock. BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Leerink Swann boosted their target price on Uniqure from $19.00 to $26.00 in a research note on Tuesday, November 7th. Finally, Zacks Investment Research upgraded Uniqure from a “sell” rating to a “hold” rating and set a $21.00 target price on the stock in a research note on Tuesday, October 24th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Uniqure currently has a consensus rating of “Buy” and an average price target of $20.00.
The company has a market cap of $558.41, a P/E ratio of -6.95 and a beta of 0.72. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in Uniqure by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after acquiring an additional 61,650 shares in the last quarter. Mangrove Partners increased its position in shares of Uniqure by 167.4% during the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after purchasing an additional 66,763 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 14,659 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in shares of Uniqure during the 3rd quarter worth approximately $399,000. Hedge funds and other institutional investors own 24.87% of the company’s stock.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with Analyst Ratings Network's FREE daily email newsletter.